Drug Resistance in Epilepsy
Lessons from Oncology
1st Edition
Published on 25. March 2002
Book
Hardback
256 pages
978-0-470-84146-4 (ISBN)
Description
The object of this book is to gather together workers in the fields of epilepsy, those concerned with the basic science of resistance and the blood-brain barrier, and those with clinical experience of drug resistance in cancer, with a view to stimulating further work on drug resistance in epilepsy. Whilst resistance in cancer has been extensively studied, and trials of reversal of resistance have been undertaken, with some success, resistance in epilepsy has only just begun to be addressed.
More details
Series
Language
English
Place of publication
New York
United States
Target group
College/higher education
Professional and scholarly
Product notice
sewn/stitched
Cloth over boards
Dimensions
Height: 235 mm
Width: 155 mm
Thickness: 18 mm
Weight
526 gr
ISBN-13
978-0-470-84146-4 (9780470841464)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
Content
Chair's Introduction (V. Ling).
The problem of the drug-resistant epilepsies (J. W. Sander).
Drug resistance molecules: lessons from oncology (George L.Scheffer and Rik J. Scheper).
Drug resistance in epilepsy: the role of the blood-brain barrier(N. Joan Abbott, et al.).
P glycoprotein and the mechanism of multidrug resistance (A.Varadi, et al).
Drug resistance caused by multidrug resistance-associated proteins(J. Wijnholds).
Reversal of multidrug resistance: lessons from clinical oncology(S. E. Bates, et al.).
Clinical development of P glycoprotein modulators in oncology (A.Oza).
Gene expression profiling of epothilone A-resistant cells (P.Atadja, et al.).
Imaging of P glycoprotein function in vivo with PET (N. H.Hendrikse and W. Vaalburg).
Animal models of drug-resistant epilepsy (W. Loscher).
Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, etal).
Cellular mechanisms of pharmacoresistance in slices from epilepsysurgery (R. A. Deisz).
Functional polymorphisms of the human multidrug resistance (MDR1)gene: correlation with P glycoprotein expression and activity invivo (U. Brinkmann).
OC144-093, a novel P glycoprotein inhibitor for the enhancement ofanti-epileptic therapy (M. J. Newman, et al.).
Closing remarks (V. Ling).
Index of contributors.
Subject Index.
The problem of the drug-resistant epilepsies (J. W. Sander).
Drug resistance molecules: lessons from oncology (George L.Scheffer and Rik J. Scheper).
Drug resistance in epilepsy: the role of the blood-brain barrier(N. Joan Abbott, et al.).
P glycoprotein and the mechanism of multidrug resistance (A.Varadi, et al).
Drug resistance caused by multidrug resistance-associated proteins(J. Wijnholds).
Reversal of multidrug resistance: lessons from clinical oncology(S. E. Bates, et al.).
Clinical development of P glycoprotein modulators in oncology (A.Oza).
Gene expression profiling of epothilone A-resistant cells (P.Atadja, et al.).
Imaging of P glycoprotein function in vivo with PET (N. H.Hendrikse and W. Vaalburg).
Animal models of drug-resistant epilepsy (W. Loscher).
Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, etal).
Cellular mechanisms of pharmacoresistance in slices from epilepsysurgery (R. A. Deisz).
Functional polymorphisms of the human multidrug resistance (MDR1)gene: correlation with P glycoprotein expression and activity invivo (U. Brinkmann).
OC144-093, a novel P glycoprotein inhibitor for the enhancement ofanti-epileptic therapy (M. J. Newman, et al.).
Closing remarks (V. Ling).
Index of contributors.
Subject Index.